Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement

About this update from Pentixapharm Holding Ag

Berlin - Pentixapharm Holding AG has completed the rights offering carried out as part of its capital increase announced on 1 July 2026 . Subscription rights were exercised for the issue of 9,096,771 new shares, including the option offered to shareholders to acquire further new shares by way of so-called oversubscription. This corresponds to a share of 82.5% of the planned total volume of the capital increase. Based on the subscription offer alone (including the so-called oversubscription), the company will receive gross proceeds of around EUR 16.8 million . The Company intends to use the net proceeds to finance key steps of the PANDA Phase 3 study as well as the company's further development and expansion in the U.S. market. In the opinion of the Management Board, this gives the company a good starting position for the intensified examination of partnership and out-licensing options, especially in the USA . The unsubscribed shares remaining of the 1,923,441 new shares offered will be offered to institutional investors until July 28, 2026 by way of a private placement in Germany and certain other jurisdictions outside the Federal Republic of Germany at the placement price of EUR 1.85 per new share. In addition to financing the PANDA study, part of the net proceeds will be used for further corporate development and expansion in the US market, as well as for further preparation of clinical development and to strengthen the manufacturing and supply infrastructure. This is intended to support the late-stage clinical development of the company's programs and further expand the basis for possible future commercialization. Contact: Email: [email protected] Important note This announcement does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities. A public offer will be made exclusively in accordance with the published subscription offer and the Annex IX document. This announcement is not for publication, distribution or dissemination in or into the United States of America , Australia , Canada , Japan or any other jurisdiction in which such publication, distribution or dissemination would be unlawful. The New Shares have not been and will not be registered under the U.S . Securities Act of 1933, as amended (the 'Securities Act') and may not be offered or sold in the United States of America or to or for the account or benefit of U.S . persons absent registration under the Securities Act or an exemption from the registration requirements of the Securities Act. There will be no public offering of the shares in the United States of America . (C) 2026 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Pentixapharm Holding Ag